Ved 48 uger var tallene 25, 2% for patienterne i APTIVUS/ ritonavir- gruppen og 15, 6% i komparatorgruppen.
At 48 weeks these rates were 25.2% of patients in the APTIVUS/ ritonavir arm and 15.6% in the comparator arm.